Hepatitis/MASH

Treating hepatitis C could potentially be less expensive with generic treatments.

Treating hepatitis C could potentially be less expensive with generic treatments.

Tenofovir alafenamide found safer than tenofovir disoproxil fumarate in multiple trials.

Overall positive results shown in studies with Harvoni and sofosbuvir/velpatasvir.

Overall positive results shown in studies with Harvoni and sofosbuvir/velpatasvir.

A typcial treatment regimen for hepatitis C virus lasts 12 weeks at a high cost.

Current treatment options for patients who previously failed HCV therapy are limited.

Current treatment options for patients who previously failed HCV therapy are limited.

Some genetic variants have the potential to affect responses to immunosuppressive drugs that influence organ rejection.

HCV-related deaths continued to rise while deaths from 60 other infectious diseases declined.

Novel drug RG-101 could shorten the treatment time for hepatitis C virus (HCV) infection to 4 weeks.

Zepatier achieves sustained virologic response rate of 99.2% during a 12 to 16 week treatment course in patients with HCV.

Top news of the day from across the health care landscape.

HCV testing rises in substance use disorder treatment programs.

Zepatier boasts sustained virologic response rates of 99% in hepatitis C genotypes 1 and 4.

Zepatier boasts sustained virologic response rates of 99% in hepatitis C genotypes 1 and 4.

Researchers consider whether eradicating HCV and HBV is an obtainable goal given the high cost of antiviral drugs.

Avella Specialty Pharmacy has launched two innovative apps to help providers select the most appropriate specialty drug options for hepatitis C and oncology patients.

Descovy is not a complete regimen and must be used in combination with other antiretroviral agents for the treatment of HIV.

California man with osteogenesis imperfecta beats HCV after treatment with Harvoni.

HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.

One clinic found little value in the early testing of infants born to HCV-infected mothers.

Is sofosbuvir plus ribavirin a viable option for hepatitis C virus therapy after liver transplant?

Study finds a common assortment of reasons for non-initiation of hepatitis C therapy, regardless of patient race or ethnicity.

Aberrant protein mutation associated with the black plague may lead to treatments for HIV and hepatitis C.